Abstract
More efficient immunosuppressive medication has markedly improved both graft and patient survival after renal transplantation. However, more potent immunosuppressants also have detrimental effects, such as increasing the risk of infection and cancer. Emphasis should therefore be placed on interventions that reduce the risk of rejection, graft dysfunction and patient death without increasing the immunosuppressive load. This has been clearly validated for better HLA matching between the donor and recipient, shorter cold ischemia times and improving organ preservation by machine perfusion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Transplant international : official journal of the European Society for Organ Transplantation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
